Targeting the sheddase activity of Adam17 by an Anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation

International Journal of Biological Sciences

Volumn 10, Issue 7, 2014, Pages 702-714

  Huang, Yanchao ^a,b   Benaich, Nathan ^a,d   Tape, Christopher ^a,e   Kwok, Hang Fai ^a,c   Murphy, Gillian ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IONTAS LTD   (United Kingdom)

^c UNIVERSITY OF MACAU   (Macao)

^d GUY S HOSPITAL   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

ADAM17; Cell proliferation and motility; HER receptor and ligands; Inhibitory antibody

Indexed keywords

ADAM PROTEIN; ADAM10 PROTEIN, HUMAN; ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MEMBRANE PROTEIN; QUINAZOLINE DERIVATIVE; SECRETASE; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENE SILENCING; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIBODIES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ERBB RECEPTORS; GENE KNOCKDOWN TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; MEMBRANE PROTEINS; PHOSPHORYLATION; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 84902977036     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.9326     Document Type: Article

References (51)

1. Chin D., Boyle GM, Porceddu S, et al. Head and neck cancer: past, present and future. Expert Review of Anticancer Therapy 2006; 6: 1111-18.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nature Reviews: Cancer. 2011, 11: 9-22.
3. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumour development: EGFR gene and cancer. FEBS Journal. 2010; 277: 301-8.
4. Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocrine-related Cancer. 2005; 12: S17-27.
5. Hegymegi-Barakonyi B, Eros D, Szantai-Kis C, et al. Tyrosine kinase inhibitors-small molecular weight compounds inhibiting EGFR. Current Opinion in Molecular Therapeutics. 2009; 11: 308-21.
6. Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Current Cancer Drug Targets. 2007; 7: 650-65.
7. Zimmermann M, Zouhair A, Azria D, et al. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiation Oncology. 2006; 1: 11.
8. Rabinowits G, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncology. 2012; 48: 1085-89.
9. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature Reviews: Clinical Oncology. 2010; 7: 493-507.
10. Box C, Zimmermann M, Eccles S. Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers. Front Biosci. (Landmark Ed). 2013; 18: 520-42.
11. Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histology and Histopathology. 2005; 20: 1005-15.
12. Huang Z, Brdlik C, Jin P, et al. A pan-HER approach for cancer therapy: background, current status and future development. Expert Opinion on Biological Therapy. 2009; 9: 97-110.
13. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008; 27: 3944-56.
14. Barnea I, Haif S, Keshet R, et al. Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies. Head & Neck. 2013; 35: 399-407.
15. Black RA. Tumour necrosis factor-alpha converting enzyme. International Journal of Biochemistry & Cell Biology. 2002; 34: 1-5.
16. Lee DC, Sunnarborg SW, Hinkle CL, et al. TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann. New York Acad. Sci. 2003; 995: 22-38.
17. Zheng X, Jiang F, Katakowski M, et al. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol. Ther. 2009; 8: 1045-54.
18. Lendeckel U, Kohl J, Arndt M, et al. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. Journal of Cancer Research and Clinical Oncology. 2005; 131: 41-8.
19. Blanchot-Jossic F, Jarry A, Masson D, et al. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J. Pathol. 2005; 207: 156-63.
20. Ringel J, Jesnowski R, Moniaux N, et al. Aberrant expression of a disintegrin and metalloproteinase 17/tumour necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res. 2006; 66: 9045-53.
21. Karan D., Lin FC, Bryan M, et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int. J. Oncol. 2003; 23: 1365-71.
22. Schafer B, Marg B, Gschwind A, et al. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J. Biol. Chem. 2004; 279: 47929-38.
23. Duffy MJ, Mullooly M, O'Donovan N, et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clinical Proteomics. 2011; 8: 9.
24. Grandis JR, Chakraborty A, Zeng Q, et al. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J. Cell. Biochem. 1998; 69: 55-62.
25. Wang F, Liu R, Lee SW, et al. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene. 2007; 26: 2006-16.
26. Castillo J, Erroba E, Perugorria MJ, et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res. 2006; 66: 6129-38.
27. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Human Molecular Genetics. 2004; 13: 3029-43.
28. Kenny PA. Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. Expert Opinion on Therapeutic Targets. 2007; 11: 1287-98.
29. Kornfeld JW, Meder S, Wohlberg M., et al. Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br. J. Cancer. 2011; 104: 138-45.
30. Tape CJ, Willems SH, Dombernowsky SL, et al. Cross-domain inhibition of TACE ectodomain. Proc. Natl. Acad. Sci. USA. 2011; 108: 5578-83.
31. Richards FM, Tape CJ, Jodrell DI, et al. Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One. 2012; 7(e): 40597.
32. Lin P, Sun X, Feng T, et al. ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway. Mol. Cell Biochem. 2012; 359: 235-43.
33. An Z, Wang X, Willmott N, et al. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin. Exp. Metastasis. 1997;15:184-95.
34. Kondo N, Ishiguro Y, Kimura M, et al. Antitumour effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncology Reports. 2008; 20: 373-78.
35. Hinsley EE, Hunt S, Hunter KD, et al. Endothelin-1 stimulates motility of head and neck squamous carcinoma cells by promoting stromal-epithelial interactions. International Journal of Cancer. 2012; 130: 40-7.
36. Yang Z, Bagheri-Yarmand R, Wang RA, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clinical Cancer Research. 2004; 10: 658-67.
37. Johnson NR, Wang Y. Controlled delivery of heparin-binding EGF-like growth factor yields fast and comprehensive wound healing. Journal of Controlled Release. 2013; 166: 124-9.
38. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. Journal of Cell Biology. 2004; 164: 769-79.
39. Lerner UH, Modéer T. et al. Bradykinin B1 and B2 receptor agonists synergistically potentiate interleukin-1-induced prostaglandin biosynthesis in human gingival fibroblasts. Inflammation. 1991;15: 427-36.
40. Gschwind A, Hart S, Fischer OM, et al. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO Journal. 2003; 22: 2411-21.
41. Thomas SM, Bhola NE, Zhang Q, et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Research. 2006; 66:11831-39.
42. Greco S, Muscella A, Elia MG, et al. Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. Journal of Cellular Physiology. 2004; 201: 84-96.
43. Nam HJ, Ching KA, Kan J, et al. Evaluation of the antitumour effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Molecular Cancer Therapeutics. 2012; 11: 439-451.
44. Bonner JA, Yang ES, Trummell HQ, et al. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiotherapy and Oncology. 2011; 99: 339-343.
45. Yu Z, Weinberger PM, Sasaki C., et al. Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiology, Biomarkers & Prevention. 2007; 16: 553-8.
46. Schafer JM, Peters DE, Morley T, et al. Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin. PLoS One. 2011; 6: e20532.
47. Murumkar PR, DasGupta S, Chandani SR, et al. Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opinion on Therapeutic Patents. 2010; 20: 31-57.
48. Zhou BB, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006; 10: 39-50.
49. Zucali PA, Ruiz MG, Giovannetti E, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of Oncology. 2008; 19: 1605-12.
50. Huang MH, Lee JH, Chang YJ, et al. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Molecular Oncology. 2013; 7: 112-120.
51. Dragowska WH, Weppler SA, Qadir MA, et al. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumours irrespective of trastuzumab sensitivity. BMC Cancer. 2011; 11: 420.